anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied.
METHODS: We randomly assigned, in a 1:1 ratio, patients who had taken factor Xa inhibitors within 15 hours before having an acute intracerebral hemorrhage to receive andexanet or usual care. The primary end point was hemostatic efficacy, defined by expansion of the hematoma volume by 35% or less at 12 hours after baseline, an increase in the score on the National Institutes of Health Stroke Scale of less than 7 points (scores range from 0 to 42, with higher scores indicating worse neurologic deficit) at 12 hours, and no receipt of rescue therapy between 3 hours and 12 hours. Safety end points were thrombotic events and death.
RESULTS: A total of 263 patients were assigned to receive andexanet, and 267 to receive usual care. Efficacy was assessed in an interim analysis that included 452 patients, and safety was analyzed in all 530 enrolled patients. Atrial fibrillation was the most common indication for factor Xa inhibitors. Of the patients receiving usual care, 85.5% received prothrombin complex concentrate. Hemostatic efficacy was achieved in 150 of 224 patients (67.0%) receiving andexanet and in 121 of 228 (53.1%) receiving usual care (adjusted difference, 13.4 percentage points; 95% confidence interval [CI], 4.6 to 22.2; P = 0.003). The median reduction from baseline to the 1-to-2-hour nadir in anti-factor Xa activity was 94.5% with andexanet and 26.9% with usual care (P<0.001). Thrombotic events occurred in 27 of 263 patients (10.3%) receiving andexanet and in 15 of 267 (5.6%) receiving usual care (difference, 4.6 percentage points; 95% CI, 0.1 to 9.2; P = 0.048); ischemic stroke occurred in 17 patients (6.5%) and 4 patients (1.5%), respectively. There were no appreciable differences between the groups in the score on the modified Rankin scale or in death within 30 days.
CONCLUSIONS: Among patients with intracerebral hemorrhage who were receiving factor Xa inhibitors, andexanet resulted in better control of hematoma expansion than usual care but was associated with thrombotic events, including ischemic stroke. (Funded by Alexion AstraZeneca Rare Disease and others; ANNEXA-I ClinicalTrials.gov number, NCT03661528.).
Cardiovascular diseases, including myocardial infarction (MI), constitute the leading cause of morbidity and mortality worldwide. Protein-aggregate deposition is a hallmark of aging and neurodegeneration. Our previous study reported that aggregation is strikingly elevated in hearts of hypertensive and aged mice; however, no prior study has addressed MI effects on aggregation in heart or brain. Here, we present novel data on heart and brain aggregation in mice following experimental MI, induced by left coronary artery (LCA) ligation. Infarcted and peri-infarcted heart tissue, and whole cerebra, were isolated from mice at sacrifice, 7 days following LCA ligation. Sham-MI mice (identical surgery without ligation) served as controls. We purified detergent-insoluble aggregates from these tissues, and quantified key protein constituents by high-resolution mass spectrometry (LC-MS/MS). Infarct heart tissue had 2.5- to 10-fold more aggregates than non-infarct or sham-MI heart tissue (each P = 0.001). Protein constituents from MI cerebral aggregates overlapped substantially with those from human Alzheimer's disease brain. Prior injection of mice with mesenchymal stem cell (MSC) exosomes, shown to limit infarct size after LCA ligation, reduced cardiac aggregation ~ 60%, and attenuated markers of endoplasmic reticulum (ER) stress in heart and brain (GRP78, ATF6, P-PERK) by 50-75%. MI also elevated aggregate constituents enriched in Alzheimer's disease (AD) aggregates, such as proteasomal subunits, heat-shock proteins, complement C3, clusterin/ApoJ, and other apolipoproteins. These data provide novel evidence that aggregation is elevated in mouse hearts and brains after myocardial ischemia, leading to cognitive impairment resembling AD, but can be attenuated by exosomes or drug (CDN1163) interventions that oppose ER stress.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to chemical-pharmaceutical industry and medicine. Method includes: formation of hollow capsules, their hardening and following packing, which differs in the act that as material for manufacturing of capsules applied are substances, able to dissolve in gastric juice with speed, depending on its acidity degree, and manufacturing of capsules is carried out in chamber with increased gas atmosphere pressure. Packing of capsules can also be carried out in chamber with increased pressure, it is necessary to do packing of capsule able to preserve said pressure and provide air-tightness during fixed term of capsule storage. ^ EFFECT: increased efficiency of method of manufacturing capsules for determination of gastric juice acidity. ^ 3 cl, 1 ex
A medicine for eliminating acne is prepared from aloe, argyi leaf, flavescent sophora root, etc through mixing, immersing in 45-75% alcohol, and sealing. Automatically stirring, extracting the Chinese medicinal soaking solution, and filtering. Adding adjuvants such as salicylic acid, and filtering. And (5) standing. The liquid is brownish red clear liquid, and the supernatant fluid is taken to obtain the finished product. It has effects in removing acne, expelling pus, removing necrotic tissue, promoting granulation, caring skin, and strengthening skin.
Evapotranspiration is a key hydrological process for reducing stormwater runoff in bioretention systems, regardless of their physical configuration. Understanding the volumes of stormwater that can be returned to the atmosphere via evapotranspiration is, therefore, a key consideration in the design of any bioretention system. This study establishes the evapotranspiration dynamics of three common, structurally different, bioretention vegetation treatments (an Amenity Grass mix, and mono-cultures of Deschampsia cespitosa and Iris sibirica) compared with an un-vegetated control using lab-scale column experiments. Via continuous mass and moisture loss data, observed evapotranspiration rates were compared with those predicted by the FAO-56 Penman-Monteith model for five 14-day dry periods during Spring 2021, Summer 2021, and Spring 2022. Soil moisture reductions over the 14-day trials led to reduced rates of evapotranspiration. This necessitated the use of a soil moisture extraction function alongside a crop coefficient to represent actual evapotranspiration from FAO-56 Penman-Monteith reference evapotranspiration estimates. Crop coefficients (Kc) varied between 0.65 and 2.91, with a value of 1.0 identified as a recommended default value in the absence of treatment-specific empirical data. A continuous hydrological model with Kc=1.0 and a loading ratio of 10:1 showed that evapotranspiration could account for between 1 and 12% of the annual water budget for a bioretention system located in the UK and Ireland, increasing to a maximum of 35% when using the highest Kc observed (2.91).
After completing eligibility and baseline surveys, Lay health workers delivered an educational intervention for breast and cervical cancer screening. This educational session was delivered in participants' home and lasted between 1-2 hours. Follow-up data was collected 4-6 months post educational session.
FIELD: organic chemistry, antibiotics. SUBSTANCE: invention relates to new derivatives of erythromycin of the general formula (I)   where Z, X and Y - hydrogen; R - lower alkyl substituted with phenyl that can be substituted with one or some radicals taken from a group involving halide, lower alkyl, hydroxyl, trifluoromethyl, lower alkoxy-group, phenyl, phenoxy-group being the latter can be substituted with one or some halides; lower alkyl substituted with hydroxy-, amino-, phenoxy-group, halide, cyclohexyl, C 8 -C 12 -alkylamino- or triphenyl-(lower)-alkoxy-group; unsubstituted C 8 -C 12 -alkyl, 3,7,11-trimethyl-2,6,10-dodecatrienyl radical or C 3 -C 6 -alkenyl substituted with phenyl, biphenyl or phenoxyphenyl being at all possible stereoisomeric forms. Compounds are used in medicine as antibiotics. Invention proposes a method of synthesis of compounds of the general formula (I) that involves an interaction of compound of the formula (II)   at any of its possible stereoisomeric forms or their mixture with compound of the formula RCHO where R has values indicated in formula (I). EFFECT: improved and simplified method of synthesis. 15 cl, 81 ex
OBJECTIVE: This work assessed the impact of drug therapy combined with pulmonary rehabilitation exercise training on specific lung function and respiratory parameters of lung cancer (LC) patients after thoracoscopic lobectomy.
METHODS: 88 LC patients who had undergone thoracoscopic lobectomy were selected based on their surgical indications and health condition. The study aimed to explore methods to assist patients in their postoperative recovery; therefore, patients meeting the surgical criteria were chosen to ensure the internal validity and external applicability of the results. Meanwhile, these 88 LC patients undergoing thoracoscopic lobectomy were randomly allocated into an experimental group (EG, 44 cases) and a control group (CG, 44 cases). The EG received inhalation therapy with albuterol sulfate nebulizer solution and personalized pulmonary rehabilitation exercise training, while the CG received nebulized treatment alone. The study lasted for three months. The pulmonary rehabilitation program included regular physical exercises, including respiratory training and physical fitness training, among other activities.
RESULTS: After pulmonary lobectomy surgery, both groups of patients showed a significant decrease in (1) forced vital capacity (FVC), (2) forced expiratory volume in 1 second (FEV1), (3) maximum voluntary ventilation (MVV), and (4) peak expiratory flow (PEF). However, the values of FVC, FEV1, MVV, and PEF in the EG were significantly higher than those in the CG (P < .05). Furthermore, both groups demonstrated significant improvements in the 6-minute walk test (6MWT) results after lung lobectomy; however, the 6MWT results in the EG also significantly increased (P < .05). In terms of dyspnea index (DI), after lung lobectomy, the DI for both groups of patients significantly increased, but the DI in the EG was significantly lower than that in the CG (P < .05).
CONCLUSIONS: The combined application of drug therapy and pulmonary rehabilitation exercise training contributed to promoting cardiopulmonary function and respiratory muscle recovery in LC patients after thoracoscopic lobectomy. This was crucial for improving the quality of life of patients, as enhanced cardiopulmonary function and respiratory muscle recovery can alleviate postoperative respiratory difficulties, increase the physical stamina and activity levels of patients. This may help reduce the risk of postoperative complications, shorten hospital stays, and potentially improve long-term survival rates. Consequently, these results could have a positive impact on the development of postoperative care and treatment strategies. However, this work was subjected to several limitations, including a relatively short duration, necessitating longer-term follow-up to assess long-term effects. Additionally, the sample size was relatively small, and further large-scale research was needed to validate these findings.
In this arm of the trial individuals with facial palsy will trial the use of information and therapy guides over a 4-6 week period. They will complete measures at the start and end of this period.
1331839 Aryloxy and aryl thioalkanoic acids, amides and esters CIBA-GEIGY AG 19 April 1971 [20 March 1970] 24671/71 Heading C2C Novel aryloxy- and arylthioalkanoic acids, amides and esters of the Formula I wherein R 1 is a C 1-14 alkyl or C 5-7 cycloalkyl; R 2 is hydrogen or methyl; R 3 is OH, OM, C 1-3 alkoxy or unsubstituted amino; X and Y are independently oxygen or sulphur and M is an alkali or alkaline earth metal may be prepared by (a) condensing an alkali metal salt of II with a compound III wherein A is halogen, alkylsulphonyloxy or arylsulphonyloxy; (b) forming the free acid I by hydrolysing a functional derivative of I to form a carboxyl group at COR 3 ; (c) forming I in which R 2 is hydrogen and R 3 hydroxy by heating under hydrolysing conditions a compound IV wherein Z 1 and Z 2 are independently C 1-6 alkoxycarbonyl or nitrile, until one Z group is hydrolysed and the other is replaced by hydrogen; (d) I in which R 2 is hydrogen, heating to remove a mole of carbon dioxide from V (e), for I in which R 3 is NH 2 , reacting a compound VI wherein B is halogen or alkoxy, with ammonia; (f), for I in which R 3 is NH 2 , partially hydrolysing a nitrile group of VII to CONH 2 ; (g), for I in which R 3 is a C 1-3 alkoxy, reacting VII with a C 1-3 alkanol in the presence of water and mineral acid; (h) forming an alkali metal derivative of an alkali metal salt or a halomagnesium derivative of a halo-magnesium salt of acid VIII and reacting the organo metallic compound with a mole of R 1 A wherein A is as above; (i), for I in which R 2 is methyl and R 3 is hydroxy, reacting a compound II with a methane tri- or tetra-substituted by chlorine and/or bromine and a ketone R 1 COCH 3 or the reaction product of the latter two compounds, i.e. XI wherein Hal is chlorine or bromine, in the presence of at least a fourfold excess molar amount of a strong base and; (j) optionally converting free acids to salts with alkali- or alkaline earth metals and vice versa. The intermediates II may be formed by reacting a sodium m- or p-methoxy phenolate or thiophenolate with 2-bromo cyclohexanone to form the 2(m or p-methoxy phenoxy or phenylthiol)-cyclohexanone cyclizing the product with ortho-phosphoric acid to give 2 or 3 methoxy - 6,7,8,9 - tetrahydrodibenzo - furan or thiophene, followed by demethylation with pyridine hydrochloride. The compound II in which X is oxygen may be converted to those in which X is sulphur by forming the dimethyl thiocarbamic acid ester at the 2- or 3-position of the ring, rearranging the ester to a dimethyl carbamic acid 5-ester and hydrolysing to give II in which X is sulphur. The intermediates IV, V, VII and VIII may be prepared by processes similar to (a) above. Pharmaceutical compositions of the compounds I show hypolipaemic activity when administered orally or parenterally with the usual excipients.
[GB1331839A]
Background: The core value of healthcare education is caring. However, caring traits are learned and acquired. Service learning advocates learning by doing. Through experience learning, students are guided to learn caring attitude or caring behaviour. Thus, teachers should construct appropriate assessments to understand caring traits as a transformative process from students' learning. Teachers should also adjust the pace of teaching continuously and design appropriate courses to facilitate students' achievement of their learning goals.
The invention discloses a traditional Chinese medicine composition for treating acute radioactive skin injury. The traditional Chinese medicine composition comprises fine powders which are grinded through senecio scandens, paris polyphylla, fructus galangae, blumea balsamifera, herba aristolochiae, folium photiniae, tangerine seeds, bletilla and red peony roots. The drug is sieved through 100-mesh sieve and added with appropriate honey to be manufactured to be paste, irradiation field area skin is carried out on a treatment of topical application of the drug, and a control group adopts a method of a conventional radioactive skin treatment. A clinical test is proved, skin reaction occurrence rates of the treatment group in the fifth day, the tenth day and the fifteenth day of the drug using are respectively 32.9%, 43.4% and 44.7%; skin reaction occurrence rates the control group in the fifth day, the tenth day and the fifteenth day are respectively 55.5%, 71.1% and 87.0%. Through observation, the traditional Chinese medicine composition is thought to have an obvious curative effect on prevention and treatment of cervical cancer radiation patient acute radioactive skin injury. By the adoption of a method of continuous topical application of the drug, the time of skin contacting the drug is long, absorption is easy, and cost is low. The traditional Chinese medicine composition is worthy to be popularized.
RETROVIR should be used with caution in patients who have bone marrow compromise evidenced by granulocyte count less than 1,000 cells per mm3 or hemoglobin less than 9.5 g per dL. Hematologic toxicities appear to be related to pretreatment bone marrow reserve and to dose and duration of therapy. In patients with advanced symptomatic HIV-1 disease, anemia and neutropenia were the most significant adverse events observed. In patients who experience hematologic toxicity, a reduction in hemoglobin may occur as early as 2 to 4 weeks, and neutropenia usually occurs after 6 to 8 weeks. There have been reports of pancytopenia associated with the use of RETROVIR, which was reversible in most instances after discontinuance of the drug. However, significant anemia, in many cases requiring dose adjustment, discontinuation of RETROVIR, and/or blood transfusions, has occurred during treatment with RETROVIR alone or in combination with other antiretrovirals.

Frequent blood counts are strongly recommended to detect severe anemia or neutropenia in patients with poor bone marrow reserve, particularly in patients with advanced HIV-1 disease who are treated with RETROVIR. For HIV-1-infected individuals and patients with asymptomatic or early HIV-1 disease, periodic blood counts are recommended. If anemia or neutropenia develops, dosage interruption may be needed [see Dosage and Administration (2.4)].
AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week that paclitaxel is given + paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
The invention belongs to the field of antiviral drugs and provides an application of a fatty-based ester compound WY124 in preparing an anti-enterovirus drug. The fatty-based ester compound is a compound as shown in WY124. Through an inhibitory activity research experiment of the compound WY124 on EV71 and CVB3, cytopathic effects (CPE) generated by EV71 and CVB3 separately on host cells RD and Hep-2 are inhibited, the cell survival rate is enhanced, the output of the EV71 progeny viruses is reduced, and the host cell apoptosis caused by EV71 infection can be inhibited. Through a pharmacological study of inhibiting EV71 by WY124, the WY124 mainly inhibits the copying stage of EV71 in the host cells. The novel fatty-based ester compound WY124 has a potential of preparing the anti-enterovirus drug. The compound is simple in synthetic process, economic and rapid and suitable for large-scale production, and has a clinical application prospect.
OBJECTIVE: Fibular free flap necrosis (FFFN) is the most common complication in patients with osteoradionecrosis (ORN) after mandibular reconstruction surgery. However, there are no effective forecasting tools at present. This research is aimed to establish and verify a nomogram model to predict the risk of FFFN after mandibular reconstruction surgery in ORN patients.
METHODS: A total of 193 ORN patients with mandibular reconstruction using fibular free flap (150 cases in the model group and 43 cases in the validation group) were enrolled in this study. In the model group, the variables were optimized by lasso regression. Then the prediction model was established by binary logistic regression analysis, and the nomogram was drawn. The bootstrap self-sampling method was used for internal verification. Moreover, 43 cases in the validation group were used for external validation.
RESULTS: The results of lasso regression and binary logistic regression analysis showed that the radiotherapy interval (≤2 years), trismus, diabetes, without deep venous anastomoses, and American society of anesthesiologists (ASA) III were the independent risk factors for FFFN after mandibular reconstruction surgery in ORNJ patients (P<0.05). Based on the above-mentioned risk factors, the nomogram model was established. The AUC values of the model group and the validation group were 0.936 and 0.964, respectively. The curve analysis showed that when the probability thresholds of the model group and the validation group were 5.699%∼98.229% and 0.413%∼99.721%, respectively. So the patient's clinical net profit rate was the highest.
CONCLUSION: A nomogram combining the factors of radiotherapy interval (≤2 years), trismus, diabetes, without deep venous anastomoses, and ASA III provided a comparatively effective way to predict the risk of FFFN after mandibular reconstruction surgery in ORN patients, which has distinct applied clinical value.
Lumoral treatment is a CE-marked medical device developed to provide a potent, targeted antibacterial action on dental plaque in a home environment. The device mechanism of action is antibacterial photodynamic therapy. The device is used by swishing a mouth rinse, strongly adhering to dental plaque. The plaque-adhered photoactive mouth rinse can be activated by a simple use light applicator. The antibacterial efficacy far exceeds chlorhexidine, without side effects in long-term use. Preliminary results have shown a promising anti-inflammatory response in addition to plaque reduction.

This early-stage study is designed to determine the efficacy of the Lumoral method in periodontitis patients. Improved supragingival plaque control can help to also sustain subgingival plaque management in the long term. In addition, the device might have a photobiomodulation effect on periodontal tissues.
Since computed tomography (CT) is a part of standard diagnostic protocol in pancreatic ductal adenocarcinoma (PDAC), we have evaluated the value of CT for sarcopenia screening in patients with PDAC, intending to expand the diagnostic value of tomographic studies. In our study, we included 177 patients with available CT images. Two groups were formed: Group 1 consisted of 117 patients with PDAC in various locations and stages and Group 2, or the control group, consisted of 60 "nominally healthy" patients with other somatic non-oncological diseases. The body mass index (BMI) was defined as a ratio of patient's weight to the square of their height (kg/m2). CT-based body composition analysis was performed using commercially available software with evaluation of sarcopenia using skeletal muscle index (SMI, cm2/m2). Based on the SMI values, sarcopenia was found in 67.5% of patients (79 out of 117) in the first patient group. It was found more frequently in males (42 out of 56; 75%) than in females (37 out of 61; 60.6%). Additionally, we observed a decrease in muscle mass (hidden sarcopenia) in 79.7% in patients with a normal BMI. Even in overweight patients, sarcopenia was found in 50% (sarcopenic obesity). In patients with reduced BMI sarcopenia was found in all cases (100%). Statistically significant difference of SMI between two groups was revealed for both sexes (p = 0,0001), with no significant difference between groups in BMI. BMI is an inaccurate value for the assessment of body composition as it does not reflect in the details the human body structure. As SMI may correlate with the prognosis, decreased muscle mass- especially "hidden" sarcopenia or sarcopenic obesity- should be reported. The use of CT-based evaluation of sarcopenia and sarcopenic obesity will allow for a better treatment response assessment in patients with cancer cachexia.